REG - Pathfinder Minerals - Entry into revised SPA for sale of IM Minerals

Pathfinder MineralsAnnouncement

28/07/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230728:nRSb6204Ha&default-theme=true

RNS Number : 6204H  Pathfinder Minerals Plc  28 July 2023

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK Market Abuse
Regulation

 

28 July 2023

 

Pathfinder Minerals Plc

("Pathfinder" or the "Company")

 

Entry into revised SPA for sale of IM Minerals

 

Pathfinder Minerals Plc, the Southern Africa focused natural resource company,
is pleased to announce it has entered into a revised sale and purchase
agreement ("Revised SPA") with Acumen Advisory Group LLC ("AAG) in respect of
the disposal of IM Minerals Limited ("IMM") (the "Disposal") and, with it, the
rights to bring a claim against the Government of Mozambique for the
expropriation of Mining Concession 4623C (the "Claim").

 

Highlights

 

·      Pursuant to the Revised SPA, Pathfinder will receive:

o  a larger contingent payment of the greater of US$30 million (previously
US$24 million) or 25% (previously 20%) of the aggregate amount payable on
settlement or determination of the Claim; and

o  an initial consideration of £1 million (previously £2 million) on
completion of the Revised SPA ("Completion"), with such funds having already
been deposited in full in the Company's solicitor's client account

·      All other material terms of the SPA remain as previously
announced in the 25 May 2023 circular available on the Company's website at
www.pathfinderminerals.com (http://www.pathfinderminerals.com)

 

Completion of the Revised SPA ("Completion") is conditional upon shareholder
approval being received at a general meeting of the Company (the "General
Meeting"), in line with AIM Rule 15, for the disposal of IMM, to be held on or
before 31 August 2023, with Completion due on the date falling two business
days from the passing of the requisite resolution (or on such other date as is
agreed in writing by the Company and AAG). A further announcement will be made
by the Company upon publication of the necessary circular and notice of
General Meeting.

 

Dennis Edmonds, Chairman, commented:

 

"The new consideration structure better reflects the long-term potential value
of the Claim while providing shareholders confidence that we can, subject to
shareholder approval, complete the Disposal in the knowledge that the full
funds are already in the Company's solicitors' client account. The Board are
currently taking legal and tax advice to ensure any subsequent future payout
in the event of a successful resolution of the BIT claim is received almost
exclusively by Pathfinder shareholders who are shareholders of the Company at
Completion.

 

The payment of £1 million is more than sufficient to meet all the Company's
current obligations and will also substantially contribute to the costs of any
future transaction."

 

Detailed terms and conditions of the Revised SPA

 

The consideration payable by AAG to the Company is £1 million on Completion
and the greater of US$30 million or 25% of the aggregate amount (including all
deferred or conditional payments) payable on settlement or determination of
the Claim less all reasonable costs and expenses properly incurred in respect
of the Claim ("Deferred Consideration").

 

Under the Revised SPA, AAG confirms that it has secured funding for at least
US$15 million to fund the Claim and undertakes to the Company that it will:

a)    instruct lawyers to commence legal proceedings and issue a claim in
respect of the Claim within three months of Completion;

b)    use its best endeavours to settle and/or finalise the Claim within
five years of Completion; and

c)    keep the Company informed of material developments in respect of the
Claim.

 

Under the Revised SPA, the Company agrees that, if requested by AAG, it will
use reasonable endeavours insofar as it is reasonably able, to assist AAG with
a divestment to a third party of any licences which are returned or awarded to
it in respect of the Claim.

 

The Company has provided AAG with certain warranties under the Revised SPA
with its aggregate liability capped at £2 million. Any individual claim for
breach of these warranties must exceed £20,000 and all such claims together
must exceed £200,000 before a claim for breach of warranty can be brought
(when the whole amount can be claimed) and any such claim for breach of
warranty must be notified by AAG to the Company within 12 months of
Completion.

 

AIM Rule 15

 

On Completion, the Company will cease to own, control, or conduct all or
substantially all of its existing trading business, activities or assets and
will become an AIM Rule 15 cash shell. As such, the Company will be required
to make an acquisition or acquisitions which constitute a reverse takeover
under AIM Rule 14 (including seeking a re-admission as an investing company
(as defined under the AIM Rules)) on or before the date falling six months
from Completion and be re-admitted to trading on AIM as an investing company
under the AIM Rules for Companies (the "AIM Rules") (which requires the
raising of at least £6 million), failing which the Company's ordinary shares
would then be suspended from trading on AIM pursuant to AIM Rule 40.

 

Accordingly, should the Disposal complete, the Company will become an AIM Rule
15 cash shell and will evaluate opportunities in the sectors the directors
consider appropriate, seeking to identify one or more projects or assets which
the Company can acquire, which would constitute a reverse takeover under AIM
Rule 14. While the initial consideration to be received has been reduced from
£2.0 million to £1.0 million, the directors are confident that the initial
consideration payable in respect of the Disposal of £1 million will be
sufficient to cover the costs of a reverse takeover under AIM Rule 14 and
provide initial working capital for the then enlarged group.

 

Any reverse takeover transaction will require the publication of an AIM Rules
compliant admission document and will be subject to shareholder approval at a
further general meeting of the Company to be convened at the appropriate time.

 

The Board will seek to preserve the right to the Deferred Consideration for
the benefit of shareholders who are recorded on the Company's shareholder
register at the time of Completion.

 

Schedule Four disclosure

 

In line with the requirements of Schedule Four of the AIM Rules, IMM has no
trading profits or losses, and its assets have been fully impaired. As at 31
December 2022 (and at the date hereof), the profits attributable to IMM are
£nil (2021: £nil) and the gross assets of IMM were £nil (2021: £nil). The
Disposal will therefore have no impact on the Company's consolidated financial
position, save that the Company will reflect a gain on the disposal of IMM.

 

Further update to recent board change

 

On 23 June 2023, the Company announced, amongst other matters, that Peter
Taylor had resigned as a director of the Company ahead of the commencement of
the Annual General Meeting and that Mr Taylor will remain as an employee of
the Company in the capacity as Chief Executive Officer and will continue as a
director of its subsidiary companies, including IMM. In light of the progress
made in relation to the Revised SPA, the Directors of the Company have now
agreed with Mr Taylor that he will resign as CEO on Completion but will remain
a director of IMM and be available to assist AAG in driving forward the Claim.
 

 

Enquiries:

 

Allenby Capital Limited (Nominated Adviser and Broker)

John Depasquale / Vivek Bhardwaj (Corporate Finance)

Stefano Aquilino / Joscelin Pinnington (Sales & Corporate Broking)

Tel. +44 (0)20 3328 5656

 

Vigo Consulting (Investor Relations)

Ben Simons / Kate Kilgallen

Tel. +44 (0)20 7390 0234

Email. pathfinderminerals@vigoconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEVLFLXDLFBBL